Showing 3691-3700 of 4164 results for "".
- CORE Highlights Emerging Focus on Pre-Myopia in Latest Contact Lens Updatehttps://modernod.com/news/core-highlights-emerging-focus-on-pre-myopia-in-latest-contact-lens-update/2484173/The Centre for Ocular Research & Education (CORE) has released the newest edition of Contact Lens Update, spotlighting the growing clinical and scientific interest in pre-myopia. This evolving area of study is reshaping how clinicians assess risk, intervene ear
- J&J to Present New Data Demonstrating Superiority of Acuvue Oasys Max 1-Day for Astigmatism at AAOpthttps://modernod.com/news/jj-to-present-new-data-demonstrating-superiority-of-acuvue-oasys-max-1-day-for-astigmatism-at-aaopt/2484158/Johnson & Johnson announced new clinical data demonstrating significantly higher end-of-day comfort and stronger overall patient preference for the Acuvue Oasys Max 1-Day for Astigmatism contact lenses compared to Dailies Total1 for Astigmatism.
- Ollin Biosciences Launches with $100 Million to Advance Next-Generation Ophthalmic Therapieshttps://modernod.com/news/ollin-biosciences-launches-with-100-million-to-advance-next-generation-ophthalmic-therapies/2484145/Ollin Biosciences has emerged from stealth with $100 million in initial financing. Ollin is assembling a robust pipeline of both clinical and late-stage preclinical programs, building upon validated biologies to better address unmet treatment needs in oph
- Kalaris Therapeutics Launches Phase 1b/2 Dose-Finding Trial of TH103 for Wet AMDhttps://modernod.com/news/kalaris-therapeutics-launches-phase-1b2-dose-finding-trial-of-th103-for-wet-amd/2484144/Kalaris Therapeutics has initiated patient enrollment in a phase 1b/2 multiple ascending dose (MAD) clinical study of TH103, its investigational therapy for wet age-related macular degeneration (AMD). The phase 1b/2 t
- Inflammasome Therapeutics Reports Encouraging Early Results for K8 in Geographic Atrophyhttps://modernod.com/news/inflammasome-therapeutics-reports-encouraging-early-results-for-k8-in-geographic-atrophy/2484139/Inflammasome Therapeutics, which is developing a new class of inflammasome inhibitors known as Kamuvudines, announced promising early clinical data for its lead ophthalmic candidate K8. Delivered via a sustained-release intraocular implant, K8 reduced geograph
- jCyte Initiates Patient Dosing in Phase 2 JC02-88 Trial of jCell for RPhttps://modernod.com/news/jcyte-initiates-patient-dosing-in-phase-2-jc02-88-trial-of-jcell-for-rp/2484125/jCyte announced that the first patients have been enrolled and treated in the JC02-88 study, a phase 2 clinical trial evaluating the safety and efficacy of jCell (famzeretcel) for the treatment of retinitis pigmentosa (RP). The study is testing a jCell dose about 5
- FDA Clears IND for Opus Genetics’ OPGx-BEST1 Gene Therapy Candidatehttps://modernod.com/news/fda-clears-ind-for-opus-genetics-opgx-best1-gene-therapy-candidate/2484123/Opus Genetics announced that the FDA has accepted its investigational new drug (IND) application for OPGx-BEST1, a gene therapy for the treatment of bestrophin-1 (BEST1)-related inherited retinal diseases (IRDs). The company now plans to initiate a Phase 1/2 clinical trial in the second
- 4DMT Provides New 60-Week Results for Gene Therapy Candidate for DMEhttps://modernod.com/news/4dmt-provides-new-60-week-results-for-gene-therapy-candidate-for-dme/2482922/4D Molecular Therapeutics (4DMT) announced interim results from its SPECTRA phase 2a clinical trial evaluating 4D-150 for diabetic macular edema (DME). The data were presented at the 43rd Annual American Society of Retina Specialists (ASRS) scientific mee
- Alcon Showcases Surgical Efficiency of Unity VCS Innovations at ASRS 2025https://modernod.com/news/alcon-showcases-surgical-efficiency-of-unity-vcs-innovations-at-asrs-2025/2482903/Alcon will showcase its latest clinical data and innovations at the 2025 American Society of Retina Specialists (ASRS) annual meeting, July 31 to August 2, in Long Beach, California. Attendees can explore Alcon’s latest surgical advancements through scientific presentations and hands-on dem
- Orbis Flying Eye Hospital Begins 2-Week Training Project to Improve Eye Care Across Rwandahttps://modernod.com/news/orbis-flying-eye-hospital-begins-two-week-training-project-to-improve-eye-care-across-rwanda/2482898/The Orbis Flying Eye Hospital landed in Kigali, Rwanda, on July 18, 2025, marking the beginning of a historic 2-week training project. It marks the first time this aircraft has visited Rwanda, where Orbis' teams of clinical staff and volunteer faculty will work alongside t